BENGALURU — Digital-first life sciences commercialization firm Indegene Limited has formally secured shareholder approval for the appointment of Jill Mary De Simone as a Non-Executive Independent Director. The resolution was approved during the company’s 28th Annual General Meeting (AGM).
De Simone, a biopharmaceutical executive and former President of U.S. Oncology at Merck, was originally inducted onto the board as an Additional Independent Director. The formal shareholder vote solidifies her tenure for a three-year term running from January 22, 2026, through January 21, 2029.
